Fluorescence Platform for Rapid HIV Drug Resistance Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening broadly neutralizing antibodies (bnAbs) resistance in HIV are labor-intensive, technically complex, and take too long, failing to provide rapid, high-throughput, multiplex, quantitative analyses of virion populations' sensitivity or resistance to antiviral drugs, which hinders clinical trial efficiency and effectiveness.
Innovation Solution
A fluorescence-based platform using fluorescence correlation spectrometry (FCS) with fluorescent-labeled drug conjugates to detect drug-virion interactions at a single virion level, calculating the Instantaneous Inhibition Potential (IIP) to determine the fraction of virions sensitive or resistant to drugs, and employing a multi-laser launcher, plate-based moving stage, and computing device for rapid data acquisition and processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If viral Env gene sequencing is used to screen for bnAbs resistance, then resistance information can be obtained, but the process is labor intensive, technically complex, and requires 4-6 weeks turn-around time
Solution Approach 1:
The patent replaces the mechanical/labor-intensive Env gene sequencing process with a fluorescence-based flow cytometry system. The method uses fluorescently labeled bnAbs that bind to viral Env proteins, allowing rapid detection of resistance through fluorescence intensity measurement rather than complex genetic sequencing. This substitution reduces the turn-around time from 4-6 weeks to approximately 1 week while maintaining resistance detection capability.
Solution Approach 2:
The patent changes the detection parameter from genetic sequence analysis to fluorescence intensity measurement. By using fluorescently labeled antibodies and measuring fluorescence intensity through flow cytometry, the system converts a complex molecular biology problem into a simpler physical measurement that can be performed rapidly and quantitatively, reducing both time and complexity.
2Reliability
If Env sequences are recovered and tested in pseudoviruses to demonstrate escape, then resistance can be confirmed, but the process adds more time and complexity to the analytical process
Solution Approach 1:
The patent performs preliminary binding analysis using fluorescently labeled bnAbs against the viral Env proteins in the native virus population. This preliminary fluorescence-based screening identifies potential resistance cases before more complex confirmation steps are required. The method allows for rapid triage and prioritization of samples that need further investigation, reducing the overall time required for resistance confirmation.
3Loss of information
If structured treatment interruption trials involve bnAbs administration to ART-treated subjects, then breakthrough viruses can be detected, but the subjects have little or no circulating HIV RNA to assess
Solution Approach 1:
The patent uses fluorescently labeled bnAbs as intermediaries to detect viral Env proteins even when circulating HIV RNA is low. The fluorescent antibodies bind to surface Env proteins on virions, providing a detectable signal that does not depend on high viral RNA levels in the circulation. This intermediary approach enables breakthrough virus detection in ART-treated subjects with low viral loads.
4Quantity of substance
If an outgrowth system is used to propagate replicating viruses for analysis, then virus can be obtained from ART-treated subjects, but the process adds more time to the analytical process
Solution Approach 1:
The patent extracts and analyzes viral Env proteins directly from the outgrowth system supernatant using flow cytometry, eliminating the need for additional virus isolation and characterization steps. By directly measuring fluorescence intensity in the outgrowth supernatant, the method reduces the analytical time required while still obtaining sufficient viral material for resistance assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables direct, rapid, and concurrent detection of resistance or sensitivity to multiple bnAbs in samples, significantly reducing analysis time from weeks to days, facilitating timely clinical decision-making and improving trial efficiency by providing actionable data within a practical timeframe.
Implementation Method 1
A fluorescence-based platform using fluorescence correlation spectrometry (FCS) with fluorescent-labeled drug conjugates to detect drug-virion interactions
Implementation Method 2
using fluorescence correlation spectrometry (FCS) to detect interacting drug-virion bursts at a single virion level
Data Source
AI summary
A fluorescence-based analytical platform comprising methods, software and instrumentation that accomplishes direct, rapid, high throughput, multiplex, and quantitative determinations of virion populations, in human or animals or experimental fluids, that are impacted by, or escape from, interactions with antiviral drugs. The platform can be used to advance bnAb resistance detection capacities to support numerous bnAb clinical trial activities, from screening volunteers to tailoring subject-specific bnAb combinations for treatment or cure.